Department of Gastroenterology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.
Department of General Surgery, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.
Am J Gastroenterol. 2024 Jan 1;119(1):176-182. doi: 10.14309/ajg.0000000000002499. Epub 2023 Sep 21.
Successful biliary drainage and antibiotics are the mainstays of therapy in management of patients with acute cholangitis. However, the duration of antibiotic therapy after successful biliary drainage has not been prospectively evaluated. We conducted a single-center, randomized, noninferiority trial to compare short duration of antibiotic therapy with conventional duration of antibiotic therapy in patients with moderate or severe cholangitis.
Consecutive patients were screened for the inclusion criteria and randomized into either conventional duration (CD) group (8 days) or short duration (SD) group (4 days) of antibiotic therapy. The primary outcome was clinical cure (absence of recurrence of cholangitis at day 30 and >50% reduction of bilirubin at day 15). Secondary outcomes were total days of antibiotic therapy and hospitalization within 30 days, antibiotic-related adverse events, and all-cause mortality at day 30.
The study included 120 patients (the mean age was 55.85 ± 13.52 years, and 50% were male patients). Of them, 51.7% patients had malignant etiology and 76.7% patients had moderate cholangitis. Clinical cure was seen in 79.66% (95% confidence interval, 67.58%-88.12%) patients in the CD group and 77.97% (95% confidence interval, 65.74%-86.78%) patients in the SD group ( P = 0.822). On multivariate analysis, malignant etiology and hypotension at presentation were associated with lower clinical cure. Total duration of antibiotics required postintervention was lower in the SD group (8.58 ± 1.92 and 4.75 ± 2.32 days; P < 0.001). Duration of hospitalization and mortality were similar in both the groups.
Short duration of antibiotics is noninferior to conventional duration in patients with moderate-to-severe cholangitis in terms of clinical cure, recurrence of cholangitis, and overall mortality.
成功的胆道引流和抗生素是治疗急性胆管炎的主要方法。然而,成功胆道引流后抗生素治疗的持续时间尚未得到前瞻性评估。我们进行了一项单中心、随机、非劣效性试验,比较了中度或重度胆管炎患者短期和常规抗生素治疗的效果。
连续筛选符合纳入标准的患者,并随机分为常规持续时间(CD)组(8 天)或短持续时间(SD)组(4 天)的抗生素治疗。主要结局是临床治愈(第 30 天无胆管炎复发,第 15 天胆红素降低>50%)。次要结局是抗生素治疗总天数和 30 天内住院天数、抗生素相关不良反应和第 30 天全因死亡率。
研究纳入了 120 名患者(平均年龄为 55.85±13.52 岁,50%为男性)。其中,51.7%的患者有恶性病因,76.7%的患者有中度胆管炎。CD 组临床治愈率为 79.66%(95%置信区间,67.58%-88.12%),SD 组为 77.97%(95%置信区间,65.74%-86.78%)(P=0.822)。多因素分析显示,恶性病因和发病时低血压与较低的临床治愈率相关。SD 组术后抗生素总疗程较短(8.58±1.92 和 4.75±2.32 天;P<0.001)。两组住院时间和死亡率相似。
在中度至重度胆管炎患者中,与常规持续时间相比,短疗程抗生素在临床治愈率、胆管炎复发和总体死亡率方面无差异。